ProteinLogic announces collaboration with the Immune Tolerance Network – 30 September 2008

CAMBRIDGE, UK (2008-09-30) – FOR IMMEDIATE RELEASE ProteinLogic announces collaboration with the Immune Tolerance Network CAMBRIDGE, UK (30th September, 2008) ProteinLogic Ltd. (“the Company”), announced today a collaboration with US research consortium the Immune Tolerance Network to look for disease-specific diagnostic protein fingerprints in the blood of patients with a broad range of different autoimmune diseases.

This initiative is expected to lead to a more extensive relationship between ProteinLogic and the Immune Tolerance Network that will provide the Company with access to patient samples from a wide range of US autoimmune clinical trials and if successful may result in significant advances in the diagnosis of autoimmune diseases.

The collaboration with the Immune Tolerance Network is aligned with ProteinLogic’s core strategy. It is hoped that autoimmune disease-specific protein signatures will help with the diagnosis of a wide range of autoimmune conditions.

The Immune Tolerance Network is currently planning, developing and operating 20 clinical trials in autoimmune diseases, islet, kidney and liver transplantation, allergy and asthma and operates a dozen core facilities that support these studies with state-of-the-art bioassay services.

Dr Vicky Seyfert, ITN Chief Scientific Officer said: “Markers of tolerance and of autoimmune diseases are a high priority for the ITN. We are looking forward to the results of this collaboration employing ProteinLogic’s unique approach to biomarker identification”.

Dr Richard Cumming, Global Marketing Director of ProteinLogic said: “I am delighted to announce ProteinLogic’s collaboration with the Immune Tolerance Network. ITN’s extensive network of physicians and access to samples from autoimmune clinical trials from across the US will help facilitate ProteinLogic’s expansion of its interests into the autoimmune disease area”.

Unlike conventional diagnostic tests that measure only a single or a small number of proteins, ProteinLogic’s ImmiPrint technology combines a highly optimised antibody biochip with high-throughput multiplexing technology and enables the measurement of multiple soluble blood proteins in parallel. Pattern recognition algorithms are then used to analyse the resulting protein profiles and generate disease-specific diagnostic ‘fingerprints’.

Notes for Editors.

1. ProteinLogic is a UK registered company based in Cambridge UK whose mission is to deliver diagnostic tests for use in clinical medicine. The technology ‘barcodes’ human diseases using a discrete set of biomarkers present in body fluids. The work was developed by Dr César Milstein and Dr Adrian Woolfson at MRC Laboratory of Molecular Biology in Cambridge and Professor Nick Hales from the Department of Clinical Biochemistry at the University of Cambridge. The technology is based partly on Milstein’s discovery of immune cell surface antigens and his work on monoclonal antibodies, for which he was awarded the Nobel Prize in Medicine and Physiology. The Company was spun out of the Univeristy of Cambridge, Addenbrooke’s NHS Trust and the Medical Research Council Laboratory for Molecular Biology, Cambridge. For further information, visit

2. The Immune Tolerance Network is an international research collaboration that aims to accelerate the clinical development of tolerance therapies through novel clinical trials and parallel mechanistic studies. Headquartered at the University of California, San Francisco and with offices in Bethesda, Maryland and Pittsburgh, PA, the ITN is funded by the National Institute for Allergy and Infectious Diseases, with support from the National Institute for Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation. More information on the ITN and its research can be found at

3. Dr Adrian Woolfson is a molecular biologist and medical doctor. He was the co-founder of ProteinLogic and was formerly a Charles and Katherine Darwin Research Fellow in molecular biology at Darwin College, Cambridge and a Wellcome Trust Clinical Fellow at the MRC Laboratory of Molecular Biology, Cambridge.

4. Dr César Milstein was the co-inventor of the hybridoma technique for the production of monoclonal antibodies. He was a fellow of Darwin College, Cambridge and an Honorary Fellow of Fitzwilliam College, Cambridge. From 1988 to 1995 he was the Deputy Director of the Medical Research Council Laboratory of Molecular Biology, Cambridge.

For further information, please contact:

Mr Mahesh Shah, CEO, ProteinLogic Ltd.

Phone: + 44 (0) 845 057 3906

email: or Claire Sefton, Investor Relations, ProteinLogic Ltd.

Phone: +44 07585958576

Copyright ProteinLogic Ltd September 2008